Close button
Enquiry IconContact Us
Logo
  • Choose License Type

U.S. Intravenous Immunoglobulin Market, by Formulation (Liquid and Powder), by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), is estimated to be valued at US$ 6.33 billion in 2021, and is expected to exhibit a CAGR of  6.8 %  during the forecast period (2021-2028).

Increasing number of product launches or approvals is expected to help in boosting growth of the U.S. intravenous immunoglobulin market. For instance, on January 19, 2016, Kedrion Biopharma, a company that develops plasma derived therapies announced that it had obtained exclusive rights to commercialize another immunoglobulin (IG) brand—BIVIGAM, a 10% liquid licensed by Germany-based Biotest Pharmaceuticals Corporation—in order to expand its growing presence in the U.S. Kedrion Biopharma Inc. is the U.S. subsidiary of Kedrion Biopharma, a global leader in the development and manufacturing of therapeutic plasma proteins.

Increase in number of acquisitions, partnerships, and collaborations between the market players is expected to propel the growth of the U.S. intravenous immunoglobulin market during the forecast period. For instance, on June 06, 2017, ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-based biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announced that it had completed its acquisition of the assets of Biotest Pharmaceuticals Corporation's Therapy Business Unit (BTBU). As a result of this transaction, ADMA acquired two U.S. Food and Drugs Administration (FDA) approved products, Nabi-HB (Hepatitis B Immune Globulin, Human) and BIVIGAM (Immune Globulin Intravenous, Human).

U.S. Intravenous Immunoglobulin Market- Impact of Coronavirus (COVID – 19) Pandemic

The COVID-19 pandemic has affected several markets across the globe. The COVID-19 pandemic has affected the demand and supply of healthcare products in three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and due to its financial impact on firms and financial markets.

However, impact of the coronavirus (COVID-19) pandemic is expected to boost the growth of the U.S. intravenous immunoglobulin market. For instance, according to article published in the journal International Immunopharmacology in July 2021, intravenous immunoglobulin (IVIG) showed clinical efficacy on critical ill patients with COVID-19. A relationship can be observed between efficacy of IVIG and the COVID-19 disease severity.  

Browse 35 Market Data Tables and 25 Figures spread through 210 Pages and in-depth TOC on the U.S. Intravenous Immunoglobulin Market, by Formulation (Liquid and Powder), by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by

To know the latest trends and insights prevalent in the U.S. Intravenous Immunoglobulin Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/us-intravenous-immunoglobulin-market-4829

Key Takeaways of the U.S. Intravenous Immunoglobulin Market:

  • The U.S. intravenous immunoglobulin market is expected to exhibit a CAGR of 6.8 % over the forecast period (2021-2028). Increasing research and development activities, rising product launches and approvals, inorganic activities such as collaborations, agreements, acquisitions, and others are expected to drive growth of the S. intravenous immunoglobulin market. For instance, on February 09, 2021, Evolve Biologics Inc., a plasma-derived therapeutics company, announced the completion of its adult and pediatric Phase III clinical trial of PlasmaCap IG (Intravenous Immunoglobulin or IVIG), which was conducted at 12 study centers across the U.S. and Canada. PlasmaCap IG is an IVIG replacement therapy under investigation for adult and pediatric patients with primary immune deficiency disease (PIDD).
  • Some of the major players operating in the U.S. intravenous immunoglobulin market include Biotest AG, Octapharma AG, Grifols S.A., Kedrion Biopharma, Inc., CSL Behring, McKesson Corporation, Takeda Pharmaceutical Company Limited, Bio Products Laboratory Ltd., Pfizer, Inc., and ADMA Biologics, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.